ArticleThe EMBO journal2005
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.
Article in The EMBO journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 114 citations in OpenAlex.
- Menin in Cancer.Genes · 2024Review
- Primary Human Leukemia Stem Cell (LSC) Isolation and Characterization.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- Epigenetic-Mediated Regulation of Gene Expression for Biological Control and Cancer: Cell and Tissue Structure, Function, and Phenotype.Results and problems in cell differentiation · 2022Review
- ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism.Nature communications · 2021Article
- EZH2-Targeted Therapies in Cancer: Hype or a Reality.Cancer research · 2020Review
- Targeting chromatin complexes in fusion protein-driven malignancies.Nature reviews. Cancer · 2019Review
- Targeting Epigenetics in Cancer.Annual review of pharmacology and toxicology · 2018Review
- Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia.Cold Spring Harbor perspectives in medicine · 2017Review
- Article
- Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches.Oncogene · 2017Review
- Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia.Cancer science · 2016Article
- PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity.Molecular cell · 2016Article
- The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis.International journal of molecular sciences · 2016Review
- Targeting epigenetic regulations in cancer.Acta biochimica et biophysica Sinica · 2016Review
- Review
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.Cancer research · 2015Article
- Protein lysine acetylation by p300/CBP.Chemical reviews · 2015Review
- Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Experimental hematology · 2014Review
- PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.Leukemia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
Chromosomal translocations that fuse the mixed lineage leukemia (MLL) gene with multiple partners typify acute leukemias of infancy as well as therapy-related leukemias. We utilized a conditional knockin strategy to bypass the embryonic lethality caused by MLL-CBP expression and to assess the immediate effects of induced MLL-CBP expression on hematopoiesis. Within days of activating MLL-CBP, the fusion protein selectively expanded granulocyte/macrophage progenitors (GMP) and enhanced their self-renewal/proliferation. MLL-CBP altered the gene expression program of GMP, upregulating a subset of genes including Hox a9. Inhibition of Hox a9 expression by RNA interference demonstrated that MLL-CBP required Hox a9 for its enhanced cell expansion. Following exposure to sublethal gamma-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myeloproliferative disorders. These represented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/myeloproliferative disorder similar to that seen in humans possessing the t(11;16). This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.